🟢 NeoGenomics is trading 6% up today after Q2 earnings beat and raised full-year guidance

NeoGenomics is trading 6% up at $14.20 in after-hours trading after reporting stronger-than-expected second quarter 2026 results and raising its full-year outlook.

• The company posted 11% revenue growth to $202 million and swung to a GAAP EPS of $0.02 from a prior-year loss.
• Management raised full-year 2026 revenue and adjusted EBITDA guidance, which investors are repricing positively in the after-hours session.